May 18, 2016 — The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to…
CONCLUSIONS COL6A3 could influence the viability and angiogenesis of bladder cancer cells. COL6A3 may have a certain relationship with the TGF-β/Smad-induced EMT process.
PMID: 30066698 [PubMed – in process]
Conditions: Infiltrating Bladder Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma; Stage III Bladder Urothelial Carcinoma Interventions: Drug: Gemcitabine Hydrochloride; Drug: Cisplatin; Biological: Pegfilgrastim; Procedure: Conventional Surgery; Procedure: Radical Cystectomy; Other: Chemoradiotherapy Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Not yet recruiting
ConclusionsThe results of our study demonstrate that miR-302b regulates cell functions and acts as a potential biomarker to predict recurrence in bladder cancer.
Contributors : Deepika Dhawan ; Noah M Hahn ; Jos é A Ramos-Vara ; Deborah W KnappSeries Type : Expression profiling by high throughput sequencingOrganism : Canis lupus familiarisRNA-seq was used to identify basal and luminal subtypes in canine bladder cancer. In addition to larger gene-sets, a smaller panel of genes was developed to stratify canine samples into either basal or luminal subtype prospectively. Immune signature patterns were queried in basal and luminal subtypes.
In this study, TRIM65 was first screened as an important oncogenic factor of UCB from the Cancer Genome Atlas (TCGA) database and was validated by a large cohort of clinical UCB tissues.
ConclusionsNon-urothelial cancers of the urinary bladder are rare and mostly lack established protocols for treatment. The prognosis of most of these tumors is poor because they are usually advanced at the time of diagnosis. A multimodal treatment approach should be considered to improve outcomes.
In the last decade, immunotherapy has completely changed the therapeutic armamentarium of patients with genitourinary tumors. In particular, the approval of anti-Programmed-death-1 (PD-1) agents in patients with renal cell carcinoma (RCC) and bladder cancer (BC) has increased their life expectancy, with a generally tolerated toxicity profile. On the contrary, patients with prostate cancer (PCa) seem to scarcely benefit from this strategy.
Dr. Daniel Goldstein reviews trial results comparing nab-paclitaxel to standard paclitaxel in second line treatment of bladder cancer, comparing these results to those in breast cancer and raising que…
This study aimed to investigate the effects of juglone on the human bladder carcinoma cell lines TCC-SUB and RT-4 in monolayer and spheroid cultures. Cells were treated with juglone at 24, 48, and 72 h of incubation. The activity of caspase-3 was detected in vitro using a caspase-3 colorimetric assay kit according to the manufacturer’s instructions. The bromodeoxyuridine (BrdU) labeling index was used to determine the cells of the synthesis phase. The terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling assay was used to determine the death of cells in both the monolayer and spheroid cultures. The control …
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including important studies evaluating the efficacy of neoadjuvant immunotherapy instead of chemotherapy for muscle-invasive t…